Երկիր: Կանադա
Լեզու: անգլերեն
Աղբյուրը: Health Canada
RAMIPRIL
SIVEM PHARMACEUTICALS ULC
C09AA05
RAMIPRIL
2.5MG
CAPSULE
RAMIPRIL 2.5MG
ORAL
100/500
Prescription
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
Active ingredient group (AIG) number: 0122858004; AHFS:
CANCELLED POST MARKET
2016-06-29
1 PRODUCT MONOGRAPH PR RAMIPRIL-2.5 PR RAMIPRIL-5 PR RAMIPRIL-10 RAMIPRIL CAPSULES, MANUFACTURER’S STANDARD 2.5 MG, 5.0 MG AND 10.0 MG ANGIOTENSIN CONVERTING ENZYME INHIBITOR SIVEM PHARMACEUTICALS ULC 4705 DOBRIN STREET SAINT-LAURENT, QUEBEC DATE OF PREPARATION: H4R 2P7 JANUARY 12, 2016 CONTROL NO.: 190207 2 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ....................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................. 3 INDICATIONS AND CLINICAL USE ................................................................................... 3 CONTRAINDICATIONS ........................................................................................................ 4 WARNINGS AND PRECAUTIONS ....................................................................................... 4 ADVERSE REACTIONS ....................................................................................................... 10 DRUG INTERACTIONS ....................................................................................................... 15 DOSAGE AND ADMINISTRATION ................................................................................... 17 OVERDOSAGE ...................................................................................................................... 23 ACTION AND CLINICAL PHARMACOLOGY.................................................................. 18 STORAGE AND STABILITY ............................................................................................... 26 DOSAGE FORMS, COMPOSITION AND PACKAGING .................................................. 26 PART II: SCIENTIFIC INFORMATION ............................................................................. 23 PHARMACEUTICAL INFORMATION ............................................................................... 23 CLINICAL TRIALS ......................................................................................................... Կարդացեք ամբողջական փաստաթուղթը